为确定次级挽救性静脉化疗（IVC）对难治性/复发性视网膜母细胞瘤（RB）的疗效。回顾性、非随机干预性病例系列，包括来自33名RB患者的41只眼。在33名患者中，挽救性IVC开始时的平均年龄为5岁（中位数5岁，范围2至8岁）。在展示时，根据国际视网膜母细胞瘤分类，33名患者的41只眼被分为B组（n=7，17%）、C组（n=3，7%）、D组（n=16，39%）和E组（n=15，37%）。所有患者接受了6个周期的IVC作为初级治疗。次级挽救性IVC的适应证包括复发实性肿瘤（n=36；88%）、视网膜下播散粒状种子（n=22；54%）或持续实性肿瘤（n=2；5%）。挽救性IVC的平均周期数为8个（中位数6个，范围6至18个）。在完成挽救性IVC后的平均随访期为43个月（中位数43个月，范围12至96个月），22只眼（54%）成功挽救了眼球，其中1名（3%）患者被证实存在组织学上的骨转移，并且1名（3%）患者因疑似转移而死亡。次级挽救性IVC结合适当的局部治疗可以使54%的难治性/复发性RB患者保留眼球，因此可以作为血管内化疗或摘眼手术的替代选择。

To determine the efficacy of secondary salvage intravenous chemotherapy (IVC) for refractory/recurrent retinoblastoma (RB).Retrospective, nonrandomized interventional case series of 41 eyes of 33 patients with RB.Of the 33 patients, mean age at the time of commencement of salvage IVC was 5 years (median, 5 years; range, 2 to 8 years). At presentation, RB in 41 eyes of 33 patients were classified by the International Classification of Retinoblastoma as Group B (n=7, 17%), Group C (n=3, 7%), Group D (n=16, 39%) and Group E (n=15, 37%). All patients received 6 cycles of IVC as primary treatment. The indication for secondary salvage IVC with focal treatment included recurrent solid tumor (n=36; 88%), subretinal seeds (n=22; 54%), or persistent solid tumor (n=2; 5%). Mean number of cycles of salvage IVC were 8 (median, 6; range, 6 to 18). Over a mean follow-up period of 43 months (median, 43 months; range, 12 to 96 months) after completion of salvage IVC, globe salvage was achieved in 22 (54%) eyes, 1 (3%) patient had histopathology-proven bone metastasis, and 1 (3%) patient died due to presumed metastasis.Secondary salvage IVC with appropriate focal treatment allows globe salvage in 54% eyes with refractory/recurrent RB and thus serves as an alternative to intra-arterial chemotherapy or enucleation.